Merck KGaA Company Analysis

Merck KGaA Company Analysis

  • December 2017 •
  • 28 pages •
  • Report ID: 5336339 •
  • Format: PDF
Updated analysis and forecasts based on Q3 2017 company-reported sales.

PharmaVitae explores Merck KGaA’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.

Overview – Merck KGaA’s sparse late-stage pipeline and exposure to generics mean an increased reliance on its PD-L1 therapy Bavencio.
2021 outlook – The expiries of longer-listed products will be partially offset by the launch of Bavencio and growth in emerging markets.
2026 outlook – The company will add $308m out to 2026, owing to growth in the oncology and metabolic portfolios, and the launch of Mavenclad.
Pipeline – Merck KGaA presently has no other late-stage pipeline drugs in development aside from label expansions for Bavencio.
Events – Bavencio will continue its expansion across solid tumor types as Mavenclad wins its first approval in MS.

Merck KGaA reported falling revenues in a challenging Q3 2017.
During 2016–26, Merck KGaA’s prescription pharmaceutical sales are forecast to grow by $308m as it shifts focus to Bavencio and its oncology portfolio.
Successful development of Bavencio in the immuno-oncology market is critical to biopharma revenue growth.
Merck KGaA’s CNS portfolio is expected to decline by $233m during 2016–26.

Model updates
Approval of Mavenclad in Europe.
Approval of Bavencio in the US and Europe for Merkel cell carcinoma.
Approval of Bavencio in the US for metastatic urothelial carcinoma.
Greater uptake of Glucophage in emerging markets.

Analysis structure
Explore and visualize revenue dynamics in Merck KGaA’s portfolio out to 2026 using 10-year in-house sales forecasts segmented by the following sections.

Company context
How is Merck KGaA strategically poised out to 2026?
What are Merck KGaA’s key strengths, weaknesses, opportunities, and threats?
What are Merck KGaA’s key catalysts during the current year?

Facts and figures
What is Merck KGaA’s forecasted sales performance out to 2026?
What is the revenue trajectory of Merck KGaA’s current top 10 products out to 2026?
Which therapy areas will experience the largest growth and decline?
What are the portfolio weightings of Merck KGaA based on the lifecycle of its products?

Key therapy areas
Why will specific therapy areas experience the largest growth and decline?
What are the detailed competitive dynamics at play in Merck KGaA’s important therapeutic markets?
How is Merck KGaA adapting strategically to internal and external headwinds?